Q1 EPS Estimate for Palvella Therapeutics Lowered by Analyst

Palvella Therapeutics (NASDAQ:PVLA) – Equities research analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of Palvella Therapeutics in a research note issued on Tuesday, April 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($3.56) for the quarter, down from their prior forecast of ($0.86). HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q1 2025 earnings at ($3.56) EPS, Q2 2025 earnings at ($3.79) EPS, Q2 2025 earnings at ($3.79) EPS, Q3 2025 earnings at ($4.05) EPS, Q4 2025 earnings at ($4.33) EPS, Q4 2025 earnings at ($4.33) EPS, FY2025 earnings at ($15.73) EPS, FY2025 earnings at ($15.73) EPS, FY2026 earnings at ($12.67) EPS, FY2026 earnings at ($12.67) EPS, FY2027 earnings at ($13.80) EPS, FY2027 earnings at ($13.80) EPS, FY2028 earnings at ($8.72) EPS, FY2028 earnings at ($8.72) EPS and FY2029 earnings at ($5.23) EPS.

Several other analysts have also issued reports on PVLA. Canaccord Genuity Group reiterated a “buy” rating and issued a $39.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. TD Cowen initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price for the company. Stifel Nicolaus began coverage on shares of Palvella Therapeutics in a research report on Wednesday, March 26th. They issued a “buy” rating and a $45.00 target price for the company. Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock. Finally, Scotiabank started coverage on shares of Palvella Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price on the stock. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $43.50.

Palvella Therapeutics Price Performance

Palvella Therapeutics stock opened at $23.98 on Friday. The stock has a market capitalization of $269.08 million, a PE ratio of -1.98 and a beta of 0.54. The firm has a 50 day simple moving average of $21.48. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $29.27.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors have recently made changes to their positions in PVLA. Suvretta Capital Management LLC acquired a new stake in Palvella Therapeutics in the 4th quarter valued at approximately $8,574,000. BVF Inc. IL purchased a new stake in shares of Palvella Therapeutics in the 4th quarter valued at $8,359,000. Samsara BioCapital LLC acquired a new position in Palvella Therapeutics during the 4th quarter worth about $8,154,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Palvella Therapeutics during the fourth quarter worth $7,847,000. Finally, Adams Street Partners LLC purchased a new position in Palvella Therapeutics in the fourth quarter valued at $4,916,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.